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Rupture of atherosclerotic plaque has been identified as the proximate event in the majority
of cases of acute ischemic syndromes. Plaque rupture exposes thrombogenic components of
the plaque, activating the clotting cascade and promoting thrombus formation. Future culprit
lesions are difficult to identify, however, and angiographic assessment of stenosis severity is
prone to underestimation. Compared with plaques that cause severe luminal stenosis,
vulnerable plaques may cause relatively minor stenosis, although they account for more cases
of rupture and thrombosis. Such unstable, vulnerable plaques may be associated with outward
remodeling of the vessel. Because severely stenotic plaques are more likely to stimulate
collateral circulation to the post-stenotic segment, plaque rupture and thrombosis at such sites
may be clinically silent. Characteristic histomorphologic features of vulnerable plaques
include a high lipid content, increased numbers of inflammatory cells, and extensive
adventitial and intimal neovascularity. The fibrous cap of an atherosclerotic plaque may
become thin and rupture as a result of the depletion of matrix components through the
activation of enzymes, such as matrix-degrading proteinases and cystcine and aspartate
proteases, and through the reduction in the number of smooth muscle cells. Activated T cells
may also inhibit matrix synthesis through the production of interferon-gamma. A number of
triggers of plaque rupture have been identified. Also, some thrombi may occur without
rupture of the fibrous cap. Reducing the lipid component and inflammation in atherosclerotic
plaques may help reduce the risk of plaque rupture. This may account for the clinical benefit
of risk-factor reduction gained from changes in lifestyle and from drug therapy. (J Am Coll
Cardiol 2003;41:15S–22S) © 2003 by the American College of Cardiology Foundation
Atherosclerotic cardiovascular disease is the leading cause of
death for both men and women in the U.S. and much of the
western world. Atherosclerosis is responsible for coronary
heart disease, the majority of strokes, and limb ischemia.
Although luminal narrowing by an atherosclerotic plaque
and exaggerated or anomalous vasoconstriction contribute
to some of the clinical manifestations of atherosclerotic
arterial disease, it is the superimposition of an arterial
thrombus over an underlying disrupted plaque that causes
the most acute and serious clinical manifestations of this
disease. Coronary thrombosis, therefore, is responsible for
the vast majority of acute ischemic syndromes: unstable
angina, acute myocardial infarction (MI), and sudden death
(1–5).
Plaque rupture: the basis for coronary thrombosis in
acute ischemia. A causal role for coronary thrombosis
superimposed on an atherosclerotic plaque in acute MI was
first suggested around the early 1900s. A substantial body of
data derived from angiography, surgical exploration, angios-
copy, biochemical markers, and autopsy studies in the late
1970s and early 1980s provided compelling evidence to
support the concept that coronary thrombosis was the
proximate cause for abrupt coronary occlusion leading to
acute MI, unstable angina, and many cases of sudden
cardiac death (6–17).
Several autopsy studies have demonstrated that 70% to
80% of coronary thrombi occur at sites where the fibrous cap
of an atherosclerotic plaque has ruptured, with extension of
the thrombus into the plaque as well as into the lumen, and
with propagation of the thrombus upstream from the site of
cap rupture (9,13,14,18–20). Coronary stenoses that con-
tain plaques with a ruptured fibrous cap and superimposed
thrombosis often produce a distinctive pattern on contrast
angiography characterized as a “complex lesion.” These
lesions have eccentric stenoses bearing irregular or over-
hanging margins and lucencies or filling defects (9,21).
Thus, according to current pathophysiologic concepts, rup-
ture of the fibrous cap leads to the exposure of the
thrombogenic parts of the atherosclerotic plaque, with
subsequent activation of the clotting cascade and platelet
adhesion, activation, and aggregation. This leads to throm-
bosis with an abrupt luminal compromise.
Plaque size, stenosis severity, plaque composition, and
vulnerability. Retrospective analysis of serial angiograms,
as well as prospective serial angiographic observations, have
suggested that in nearly two-thirds of all patients presenting
with acute ischemic syndromes, a coronary angiogram
performed weeks or months before the acute event had
shown the culprit lesion site to have 70% (often 50%)
diameter narrowing (1,15,16,21–27). Thus, plaques produc-
ing non-flow-limiting stenoses account for more cases of
plaque rupture and thrombosis than plaques producing a
more severe stenosis. Similarly, stress testing in stable
coronary disease patients has demonstrated that the site of
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ischemia on stress myocardial perfusion scintigraphy does
not accurately predict the future site of acute MI (28). This
seeming paradox may be attributed to the factors itemized
in the following text (29).
VULNERABLE PLAQUES MAY PRODUCE LESS LUMINAL STE-
NOSIS. Recent studies have shown that in addition to
plaque size, positive remodeling versus negative remodeling
can play an important role in determining the net effect on
lumen size. In other words, greater outward remodeling of
unstable or vulnerable plaques may minimize luminal en-
croachment despite large plaque size. Human studies using
intravascular ultrasound have, in fact, shown that outward
arterial expansion caused by positive remodeling is more
common at culprit lesion sites in unstable angina, whereas
inward or negative remodeling is more common in stable
angina (30–32). Similarly, computer models using the
Laplace Law show that larger lumens create greater circum-
ferential stress on the fibrous caps, thereby increasing their
likelihood of rupture (33).
ANGIOGRAPHIC ASSESSMENT OF STENOSIS SEVERITY IS
PRONE TO UNDERESTIMATION. This may occur because
the proximal reference segment used for stenosis severity
measurement, though presumed to be normal, may in fact
be atherosclerotic with luminal narrowing.
LESS-STENOTIC PLAQUES OUTNUMBER THE MORE SE-
VERELY STENOTIC PLAQUES. In any given coronary disease
patient, less severely stenotic plaques are 5 to 10 times more
common than severely stenotic plaques. Thus, more plaque
ruptures and thrombi may evolve from less-stenotic plaques
in part because of their larger number.
SEVERELY STENOTIC PLAQUES ARE MORE LIKELY TO STIM-
ULATE COLLATERAL CIRCULATION TO THE POST-
STENOTIC SEGMENT. Subsequent plaque rupture and
thrombosis at such sites may therefore be clinically silent
because of the protective effect of collateral recruitment.
Histomorphologic features of vulnerable plaques.
Ruptured plaques have been shown to have several histo-
morphologic features that are different from intact plaques
(Table 1). When these features are present in plaques before
rupture, they are thought to indicate vulnerability to plaque
rupture. This hypothesis is the basis for the concept of
“plaque vulnerability.” Plaques that rupture tend to be large,
to demonstrate outward or positive remodeling, have a large
lipid core often occupying 40% plaque volume, show
inflammatory cell infiltration of the fibrous cap and adven-
titia, possess a thin cap depleted of smooth muscle cells
(SMCs), and have increased neovascularity (1,3,30,34–43)
(Fig. 1).
The extracellular lipid core is composed of free choles-
terol, cholesterol crystals, and cholesterol esters derived
from lipids that have infiltrated the arterial wall and also
lipids derived from the death of foam cells. A large,
eccentric lipid core may confer a mechanical disadvantage to
the plaque by redistributing circumferential stress to the
shoulder regions of the plaque. In nearly 60% of cases, this
is the area at which fibrous caps tend to rupture (33,35,44–
46) (Fig. 2). Recent observation of selective expression of
perilipin in ruptured human plaques is of considerable
interest in this regard because perilipin inhibits lipid hydro-
lysis and could contribute to an accumulation of lipids in the
core, thereby contributing to plaque vulnerability (47). In
addition, the lipid core contains prothrombotic, oxidized
lipids and is impregnated with tissue factor derived from
macrophages. These make the lipid core materials highly
thrombogenic when exposed to circulating blood (48–52).
A number of histopathologic observations have shown
that ruptured plaques contain more inflammatory cells than
intact plaques. These cells are mostly monocyte-
macrophages, but they can be activated T cells and mast
cells and are found adjacent to the sites of cap rupture as
well as in the adventitia around areas of neovascularization
(37,53–57). Inflammatory cells are probably recruited into
the atherosclerotic plaques by adhesion molecules, such as
vascular cell adhesion molecule-1, and chemokines, such as
monocyte chemoattractant protein-1. They are then acti-
Abbreviations and Acronyms
HDL  high-density lipoprotein
MI  myocardial infarction
MMP  matrix-degrading metalloproteinase
PA  plasminogen activator
SMC  smooth muscle cell
TIMP  tissue inhibitor of metalloproteinase
Table 1. Histomorphological Features of Vulnerable Plaques
● Relatively large volume
● Outward (positive) remodeling
● Large lipid core (40% plaque volume) composed of free cholesterol
crystals, cholesterol esters, oxidized lipids impregnated with tissue
factor
● Inflammatory cell infiltration of fibrous cap and adventitia (mostly
monocyte-macrophages, some activated T cells and mast cells)
● Thin cap depleted of smooth muscle cells and collagen
● Increased neovascularity
Figure 1. Panel A shows a cross-section of the epicardial coronary artery,
demonstrating a thin fibrous cap (arrowheads) overlying a crescentic,
lipid-rich core (30). Panel B, with a higher magnification of the margin
of the cap, demonstrates dense infiltration by foamy macrophages (300)
(Hematoxylin and eosin). Copyright 2002, Massachusetts Medical Society.
All rights reserved. N Engl J Med 1997;336:1276–82.
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vated in the vessel wall. Another potential avenue for the
entry and recruitment of inflammatory cells inside the
atherosclerotic lesion may be through the adventitial neo-
vasculature, which is enhanced in atherosclerosis. Factors
that may contribute to recruitment of inflammatory cells
and their activation in atherosclerosis include oxidized
lipids, cytokines such as macrophage colony-stimulating
factor, increased angiotensin II activity, elevated arterial
pressure, diabetes, chronic infections remote from the arte-
rial wall, possible infectious organisms in the vessel wall
(e.g., Chlamydia pneumoniae, cytomegalovirus, and the like),
and activation of the immune system (4) (Table 2).
The structural components of the fibrous cap include
matrix molecules such as collagen, elastin, and proteogly-
cans, derived from SMCs. The cap protects the deeper
components of the plaque from contact with circulating
blood, but it thins out in the vicinity of a rupture. Thinning
of the fibrous cap is generally considered to be a prelude to
rupture and is a sign of vulnerability. Fibrous caps from
ruptured plaques contain less extracellular matrix (collagen
and proteoglycans) and fewer SMCs than caps from intact
plaques (38).
Atherosclerotic plaques often show increased adventitial
and intimal neovascularity, particularly those constituting
acute culprit lesions of unstable angina (43,58–63). In-
creased vascularity may provide a source for recruitment of
inflammatory cells into the plaque. Rupture of the thin-
walled vasa in the plaque intima may lead to hemorrhage,
with secondary plaque rupture.
The matrix dysregulation hypothesis of plaque rupture.
Recently, researchers have hypothesized that depletion of
matrix components—specifically, fibrillar collagens—from
the fibrous cap, caused by an imbalance between synthesis
and breakdown, leads to cap thinning. This predisposes the
fibrous cap to rupture, either spontaneously or in response to
hemodynamic or other triggers (Fig. 3) (1,35). Enhanced
matrix breakdown has been attributed primarily to a family
of matrix-degrading metalloproteinases (MMPs) that are
expressed in atherosclerotic plaques by inflammatory cells
(macrophages, foam cells) and, to a lesser extent, by SMCs
and endothelial cells (64–73). This family of enzymes can
degrade all components of the extracellular matrix and have
been shown to be catalytically active both in vitro as well as
in vivo (65,74–76). The activity of MMPs is tightly
regulated at the level of gene transcription and is also
regulated by their secretion in an inactive zymogen form
that requires extracellular activation and co-secretion of the
tissue inhibitors of metalloproteinases (TIMPs) (75). Thus,
increased gene transcription, enhanced activation, and re-
duced activity of TIMPs can individually or together create
a milieu for increased matrix proteolysis.
Latent MMPs can be activated by plasmin (produced by
the plasminogen activator [uPA] from plasminogen by
macrophages), trypsin, and chymase (derived from degranu-
lating mast cells). Increased MMP production can be
induced by oxidized lipids, reactive oxygen species, chla-
mydial heat shock protein, CD-40 ligation, inflammatory
cytokines, tenascin-C derived from macrophages, and he-
modynamic stress (56,70,71,77–83). All the components
necessary for the activation of the MMP pathway, therefore,
exist in atherosclerotic plaques. Furthermore, increased
expression of cysteine and aspartate proteases of the cathep-
sin family, as well as reduced expression of their inhibitor,
cystatin-c, in human atherosclerotic lesions, may also con-
tribute to matrix breakdown in plaques (84,85).
Matrix depletion may also result from reduced synthesis
owing to a decrease in the number of SMCs or a reduction
in their synthetic function (37,38). The activated T cell–
derived cytokine, interferon gamma, inhibits collagen gene
expression in SMCs in vitro. This suggests that activated T
cells in the plaque may inhibit matrix synthesis by producing
interferon-gamma. Several investigators have demonstrated
increased SMC death by apoptosis in human plaques, and
several key players of the death-signaling pathway have been
identified in atherosclerotic lesions (86–97). Other stimuli
that may induce SMC death in atherosclerosis include
oxidized lipids and the epidermal growth factor–like do-
main of macrophage-derived tenascin-C (normally cryptic,
Figure 2. Panel A shows a cross-section of the epicardial coronary artery,
demonstrating a rupture of the shoulder region of the plaque with a luminal
thrombus (30). Panel B, at a higher magnification than Panel A, shows
a ruptured thin cap densely infiltrated by macrophages and an adjacent
fibrin-platelet thrombus (black reflects the post-mortem injection of
contrast material) (120). In Panel C, showing an eroded plaque, a
subocclusive luminal thrombus is visible in cross-section of the epicardial
coronary artery (20). Panel D, at a higher magnification, demonstrated
a luminal thrombus (left) overlying SMC fibrin-rich plaque (100).
(Movat pentachrome) Copyright 2002, Massachusetts Medical Society. All
rights reserved. N Engl J Med 1997;336:1276–82.
Table 2. Inflammatory Mediators
● Oxidized lipids
● Cytokines
● Angiotensin II
● Increased arterial pressure
● Diabetes
● Infection (Chlamydia pneumoniae, cytomegalovirus, etc.)
● Activation of immune system
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but exposed when MMPs cleave the intact tenascin-C
molecule) (Sharifi B, personal communication).
Experimental models of plaque rupture. Despite numer-
ous attempts, no convincing animal model of spontaneous
atherosclerotic plaque rupture and thrombosis was available
until very recently. In the past, investigators have injected
catecholamines, lipopolysaccharide, and Russel’s viper
venom to trigger thrombosis in rabbits with atherosclerosis,
but such models bear little resemblance to human plaque
rupture or thrombosis (98). In another rabbit model, Re-
khter et al. (99) used a balloon incorporated in the arterial
wall to study the role of lipid accumulation and macrophage
infiltration in bringing about vulnerability to rupture. How-
ever, this model also bears little resemblance to human
disease. Similarly, endothelin injections in apo E null mice
have been shown to trigger acute myocardial necrosis, but
coronary plaque rupture and thrombosis were not the
underlying mechanism (100). Recent research with apo E
null mice revealed that there were frequent atherosclerotic
lesions resembling vulnerable plaques in the innominate
artery. Although intraplaque hemorrhage was observed,
frank rupture and thrombosis were not demonstrated (101).
Other investigators have described findings suggestive of
plaque rupture and thrombosis in the innominate artery of
apo E null mice that were fed a lard-based high-fat diet
(102). Rekhter reported evidence of plaque rupture in the
aortic plaques of apo E null mice after corticotropin-
releasing factor was injected intracranially to simulate a
stress response (presented at the annual Vascular Biology
meeting in Geneva 2000).
Over-expression of MMP-1 has failed to produce plaque
rupture in mice; paradoxical reduction in atherosclerosis was
actually observed with MMP-1 over-expression, raising
some questions about the role of MMPs as the critical
mediator of plaque rupture (103). Recently, Calara et al.
(104) reported findings suggestive of plaque rupture and
thrombosis in apo E and low-density-lipoprotein receptor
null mice, but the overall frequency was quite low. von der
Thu¨sen et al. (105) reported evidence of plaque rupture in
murine models of atherosclerosis with over-expression of
the pro-apoptotic gene p53.
Potential triggers for plaque rupture. Sudden rupture of a
vulnerable plaque may occur spontaneously without obvious
triggers. By contrast, it may follow a particular event, such
as extreme physical activity (especially in someone unaccus-
tomed to regular exercise), severe emotional trauma, sexual
activity, exposure to illicit drugs (cocaine, marijuana, am-
phetamines), exposure to cold, or acute infection (106–
114).
While plaque rupture often leads to thrombosis with the
Figure 3. Conceptual model depicting the potential pathophysiologic mechanisms of plaque vulnerability, rupture, and thrombosis. Ox-LDL  oxidized
low-density lipoprotein; MMP  matrix degrading metalloproteinases; SMC  smooth muscle cells; TF  tissue factor.
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clinical manifestations of an acute coronary syndrome, it
may also occur without clinical consequences (silent plaque
rupture). In approximately 40% of cases of acute coronary
syndrome, multiple plaque ruptures have been demonstrated
in arteries remote from the acute culprit site (115). The
thrombotic response to a plaque rupture is probably regu-
lated by the thrombogenicity of the exposed plaque constit-
uents, the local hemorheology (determined by the severity of
underlying stenosis), shear-induced platelet activation, and
also by systemic thrombogenicity and fibrinolytic activity
(1). Lipid-rich plaques may be more thrombogenic than
fibrous plaques, probably because of the high content of
tissue factor in the lipid core (52). The major source of
tissue factor appears to be the macrophage. Apoptosis of
macrophages may impregnate the lipid core with tissue
factor–laden microparticles, making the lipid-core highly
thrombogenic (50). Inflammatory cells, therefore, may be a
key factor in influencing plaque thrombogenicity.
Recent studies in our laboratory have shown that plaques
of smokers contain more tissue factor and inflammatory
cells (macrophages) than plaques of non-smokers, perhaps
contributing to the high thrombotic risk in smokers (116).
Furthermore, coronary collaterals may also influence the
clinical consequences of acute coronary occlusion. Several
investigators have suggested that organization and healing
at the site of plaque rupture and thrombosis may eventually
lead to rapid progression of plaque and worsening of
stenosis, thereby providing a mechanism for the progression
of atherosclerosis (117).
Erosion of plaque and calcified nodules as a basis for
thrombosis. Coronary thrombi have been observed overly-
ing atherosclerotic plaques in 20% to 40% of cases, without
rupture of the fibrous cap (2,13,118,119). Such thrombi
occur over plaques with superficial endothelial erosion.
These erosions are particularly common in young victims of
sudden death, in smokers, and in women. Plaques under
such thrombi have a proteoglycan-rich matrix rather than a
large lipid core, and the prevalence of inflammation is also
lower than that found in plaque rupture. The precise
mechanisms of thrombosis in this scenario are unknown. It
is conceivable that thrombosis in such cases is triggered by
an enhanced systemic thrombogenic state (enhanced plate-
let aggregability, increased circulating tissue factor levels,
depressed fibrinolytic state) (4). Activated circulating leu-
kocytes may transfer active tissue factor by shedding micro-
particles and transferring them onto adherent platelets
(120,121). It is possible that these circulating sources of
tissue factor (rather than plaque-derived tissue factor) con-
tribute to thrombosis at sites of superficial endothelial
denudation such as those found in plaque erosion. Further-
more, severe deficiencies of antithrombotic molecules,
thrombomodulin, and protein-c receptor in advanced ath-
erosclerotic lesions may also contribute to thrombosis (122).
Erosion of a calcified nodule within an atherosclerotic
plaque has also been reported as a basis—though uncom-
mon—for thrombosis.
Plaque stabilization. Several angiographic studies have
shown that risk-factor modification leads to reduced new
lesion formation, less lesion progression, and in some cases,
actual regression. However, these studies have also shown
that the magnitude of clinical-event reduction is far greater
than that accounted for by the relatively small changes in
stenosis severity. This apparent discrepancy has led to the
following hypotheses: 1) risk-factor modification may in-
duce plaque regression and reverse remodeling, with little
net change in stenosis severity; or 2) risk-factor modifi-
cation may not change plaque mass or stenosis severity
but might reduce the propensity for plaque rupture and
thrombosis by changing the composition of the plaque.
The latter possibility is referred to as “plaque stabiliza-
tion” (4,123–128). Studies in animals have in fact shown
that lowering lipids through diet, statin therapy, or direct
administration of apo A-1 and high-density lipoprotein
(HDL)-like particles, can deplete lipids, reduce inflam-
mation, sometimes reduce MMP and tissue factor levels,
and increase the collagen content of atherosclerotic
lesions (129 –136). Thus, change in plaque composition
can be achieved in animal models.
We have recently demonstrated that three months of
therapy with pravastatin also favorably modifies human
carotid plaque composition to a more stable phenotype,
providing the first human data paralleling the results from
animal models (137). It can be postulated, therefore, that
reducing lipids and inflammation in atherosclerotic plaques
may help lower the risk of plaque rupture and subsequent
thrombosis. Also, such a plaque-stabilizing effect may ac-
count for the clinical benefits of risk-factor modification
gained through changes in lifestyle and by drug therapy
(lipid-modifying drugs, angiotensin converting enzyme,
angiotensin-II receptor blockers) (4). Future additional
approaches may include direct administration of HDL and
its apolipoproteins, and novel HDL-boosting compounds
such as the rexinoids (138,139).
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